Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Silver Hammer Plans a Fall Surface and Drilling Exploration Program at the Silver Strand Project in Idaho, USA
Blue Jay Gold Intersects 14.0 m of 6.15 g/t Gold and 124 g/t Silver at Skukum Creek, Including 10.5 m of 7.84 g/t Gold and 154 g/t Silver
Blackrock Silver Receives Conditional Approval to List on The TSX and Establishes ATM Program as Longer Term Financial Alternatives
VanadiumCorp Continues the Third Year of Upstream Mineral Processing Research with Université de Sherbrooke
